Dental Care Clinics in Sallisaw, OK Accepting Medicare
6 Dental Care Clinics found. Showing 1 - 6
 Denture Today Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1290 Mentzer Ave, Sallisaw, OK 74955 Phone: 918-775-5775 Fax: 479-775-6777 |
Sout Oak Dental Care Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 201 S Oak St, Sallisaw, OK 74955 Phone: 918-775-4431 Fax: 918-775-4432 |
Aubrey J Henshaw Iii Dds Pc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 611 W Ruth Ave, Sallisaw, OK 74955 Phone: 918-775-4431 Fax: 918-775-4432 |
Randi Kennedy Gray, D.d.s., Pllc Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 504 E Cherokee Ave, Sallisaw, OK 74955 Phone: 918-776-0804 |
Diamond Smiles Dental Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1506 W Chickasaw Ave, Sallisaw, OK 74955 Phone: 918-775-3200 Fax: 918-775-0080 |
Bwdentistry Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 200 E Choctaw Ave, Sallisaw, OK 74955 Phone: 918-775-3201 Fax: 918-775-3394 |
News Archive
RXi Pharmaceuticals receives prestigious Innovation of the Year Award
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported that the Company has received Frost & Sullivan's 2009 North American RNAi Therapeutic Design & Delivery Technology Innovation of the Year Award for the development of its proprietary RNAi compounds, rxRNA™, and advanced delivery approaches.
Javelin Pharmaceuticals' Dyloject NDA receives FDA PDUFA date
Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has received an FDA PDUFA date of October 3, 2010. This NDA review is in support of US marketing approval and registration of Dyloject for the management of acute moderate-to-severe pain in adults.
GE Healthcare showcases new cardiology technology
GE Healthcare continues to re-invent and re-imagine cardiology and the innovations that may help fuel the field through the future.
MRI can be used to predict major cardiac events for people with dilated cardiomyopathy
Heart Failure impacts between three to four per cent of the general population. While commonly related to heart attacks it can also be due to a condition called dilated cardiomyopathy (DCM), a disease characterized by an enlarged and weak heart muscle that can't efficiently pump blood.
Acute stroke care and clinical outcomes improve substantially with stroke program
Acute stroke care and clinical outcomes have improved significantly at hospitals participating in the American Heart Association/American Stroke Association's Get With The Guidelines-Stroke program, according to a large study in Circulation: Cardiovascular Quality and Outcomes, a journal of the American Heart Association.
› Verified 2 days ago